Vion Biosciences, a Charlottesville, VA-based life science platform company focused on specialty reagents in the life science research, diagnostic, and drug discovery space, acquired Echelon Biosciences, a Salt Lake City, UT-based supplier of critical materials.
The amount of the deal was not disclosed.
This acquisition serves as the second investment under VION Biosciences, Iron Path Capital’s roll-up platform in the life science sector led by life science industry veteran, Mark Thornton.
Led by CEO Mark Thornton, VION Biosciences is a life science company delivering manufacturing and critical specialty chemicals and reagents alongside value-added services to enable scientific discovery, clinical testing, therapeutic development, and innovative solutions across a wide platform of key applications in the biochemical and life science sectors, from research to commercialization.
Echelon will operate as a subsidiary of VION, continuing to serve its existing customers while benefiting from VION’s resources and infrastructure. As part of the transition, the technical and commercial leadership within Echelon will remain in place. The team will be further strengthened through the additional leadership and resources brought forth by VION through the end of 2024 and into early 2025.
FinSMEs
22/08/2024